Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Tybost patent?

See the DrugPatentWatch profile for Tybost

What is the Tybost patent (and what product is it tied to)?

Tybost is the brand name for cobicistat, a medicine used to boost the effect of certain HIV medicines by inhibiting the CYP3A enzyme. Patent questions about “Tybost” typically refer to patents covering cobicistat itself and/or cobicistat’s use in combination regimens for HIV treatment. [1]

When do Tybost patents expire?

I don’t have any patent-expiration or exclusivity dates for Tybost in the information provided here. Patent timelines depend on the specific patent numbers, whether they are composition-of-matter vs. method-of-use patents, and any extensions or regulatory exclusivities tied to the product. To answer precisely, you’d need the specific patent ID(s) you’re looking at. [1]

Are there generic or biosimilar (or “same active ingredient”) options after patent expiry?

Patent expiry is what generally determines when competitors can file for and/or launch generic versions (for small-molecule drugs like cobicistat) or other covered products. Without the exact Tybost patent numbers and expiry dates, I can’t confirm what launch dates are possible for generic cobicistat. [1]

Why do people search Tybost patents (what are the common patent disputes about)?

When people search “Tybost patent,” they’re often looking for:
- whether a competitor can market a generic cobicistat before patent expiry
- what patents are listed as covering the reference product
- whether litigation or settlements affect the timing of generic entry
Those issues are usually tracked through patent lists and related legal filings, which require specific patent identifiers to interpret. [1]

Which agency records Tybost patents and exclusivity information?

Patent listings and market-exclusivity information for prescription drugs are commonly tracked through the U.S. FDA’s drug product patent and exclusivity systems (for example, via the FDA’s Orange Book), which ties patents to the listed drug and specific expiration dates. To give exact Tybost patent expiration answers, you’d check the Tybost entry and the patent list there. [1]

What do you need to get an exact Tybost patent answer?

If you share any of the following, I can pinpoint the relevant patents and explain what they cover:
- the specific patent number(s) you mean, or
- the exact listing name you’re using (e.g., “Tybost” in the FDA database), or
- the jurisdiction (U.S. vs. EU vs. UK, etc.) and whether you care about composition-of-matter vs. method-of-use

Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/ (FDA drug databases, used to look up listed drug patents/exclusivity such as via the Orange Book entry for Tybost)



Other Questions About Tybost :

Tybost generic? Tybost? Tybost cost? Tybost reviews? How to get tybost? Tybost price?

AI-Drug Label Prescribing Information Alignment Report

45
45%
Grade C

Partial

Mostly Aligned

Patient Risk: Low

Summary

Most pharmacology/label-structure statements about cobicistat and TYBOST align with the provided label excerpts (e.g., CYP3A inhibition; indications; coadministration requirement; renal monitoring concepts; contraindication framework). However, multiple claims about patent checking/Orange Book and generic entry timing are not supported or addressed by the provided prescribing information, making the response only partially aligned to the label content.


Category Scores

Indication
95
Excellent
Dosage
80
Good
Contraindications
70
Good
Warnings
75
Good
Warnings
75
Good
SpecificPopulations
85
Good
SpecificPopulations
85
Good

Accurate Statements

Tybost is the brand name for cobicistat.
Label is for TYBOST (cobicistat); Sections 12.1/12.3 describe cobicistat as the active ingredient/mechanism.
Cobicistat is a medicine used to boost the effect of certain HIV medicines by inhibiting the CYP3A enzyme.
Section 12.1 Mechanism of Action: CYP3A inhibitor increases systemic exposure of atazanavir/darunavir.
Patent questions about "Tybost" typically refer to patents covering cobicistat itself and/or cobicistat's use in combination regimens for HIV treatment.
No support in provided prescribing information excerpts (label-only evaluation).
Patent timelines depend on the specific patent numbers, whether they are composition-of-matter vs. method-of-use patents, and any extensions or regulatory exclusivities tied to the product.
No support in provided prescribing information excerpts (label-only evaluation).
Without the exact Tybost patent numbers and expiry dates, generic launch dates for generic cobicistat cannot be confirmed.
No support in provided prescribing information excerpts (label-only evaluation).
Patent expiry generally determines when competitors can file for and/or launch generic versions of small-molecule drugs like cobicistat.
No support in provided prescribing information excerpts (label-only evaluation).
People search Tybost patents to determine whether a competitor can market a generic cobicistat before patent expiry.
No support in provided prescribing information excerpts (label-only evaluation).
People search Tybost patents to determine what patents are listed as covering the reference product.
No support in provided prescribing information excerpts (label-only evaluation).
People search Tybost patents to determine whether litigation or settlements affect the timing of generic entry.
No support in provided prescribing information excerpts (label-only evaluation).
Patent listings and market-exclusivity information for prescription drugs are commonly tracked through the U.S. FDA's drug product patent and exclusivity systems (for example, via the FDA's Orange Book).
No support in provided prescribing information excerpts (label-only evaluation).
FDA's drug product patent and exclusivity systems tie patents to the listed drug and specific expiration dates.
No support in provided prescribing information excerpts (label-only evaluation).

Unsupported Statements

Patent questions about "Tybost" typically refer to patents covering cobicistat itself and/or cobicistat's use in combination regimens for HIV treatment.
Provided TYBOST prescribing information excerpts do not discuss patents or generic entry.
Patent timelines depend on the specific patent numbers, whether they are composition-of-matter vs. method-of-use patents, and any extensions or regulatory exclusivities tied to the product.
Not addressed in provided prescribing information excerpts.
Without the exact Tybost patent numbers and expiry dates, generic launch dates for generic cobicistat cannot be confirmed.
Not addressed in provided prescribing information excerpts.
Patent expiry generally determines when competitors can file for and/or launch generic versions of small-molecule drugs like cobicistat.
Not addressed in provided prescribing information excerpts.
People search Tybost patents to determine whether a competitor can market a generic cobicistat before patent expiry.
Not addressed in provided prescribing information excerpts.
People search Tybost patents to determine what patents are listed as covering the reference product.
Not addressed in provided prescribing information excerpts.
People search Tybost patents to determine whether litigation or settlements affect the timing of generic entry.
Not addressed in provided prescribing information excerpts.
Patent listings and market-exclusivity information for prescription drugs are commonly tracked through the U.S. FDA's drug product patent and exclusivity systems (for example, via the FDA's Orange Book).
Not addressed in provided prescribing information excerpts.
FDA's drug product patent and exclusivity systems tie patents to the listed drug and specific expiration dates.
Not addressed in provided prescribing information excerpts.

Contradictions


Important Omissions

No on-label claims about TYBOST indications, dosing, contraindications, warnings/precautions, drug interactions, adverse reactions, or monitoring were actually stated by the AI response (beyond general CYP3A inhibition/patent context).
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The only label-relevant safety/clinical mechanism content presented (CYP3A inhibition) does not provide unsafe dosing or contraindication misuse. Most other statements are about patents/generic timing and do not directly instruct patient use.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Mostly Aligned

Primary Issue
Several statements are outside the scope of the prescribing information (patent/Orange Book/generic entry timing) and are unsupported by the provided label excerpts.

Suggested Improvement
Limit the response to prescribing-information-supported items (e.g., TYBOST indications, coadministration/dosing requirements, contraindicated drugs/interactions, and renal monitoring statements), and omit or clearly separate non-label patent/exclusivity discussion.

Drug Brand Mention Assessment

Branding Score
46
Visibility
45
Mentioned
Ranking
#1
Sentiment
41
Recommendation Status
mentioned only
Brand Perception
Best Known For

the brand name for cobicistat


Core Claims
  • Tybost is the brand name for cobicistat
  • cobicistat is used to boost the effect of certain HIV medicines by inhibiting the CYP3A enzyme
  • Patent questions about “Tybost” typically refer to patents covering cobicistat and/or cobicistat’s use in combination regimens for HIV treatment
  • I don’t have any patent-expiration or exclusivity dates for Tybost in the information provided here
  • Patent expiry is what generally determines when competitors can file for and/or launch generic versions
Differentiators

Pricing Perception: Not Mentioned